Latest news with #ThomasJensen
Business Upturn
12-05-2025
- Business
- Business Upturn
Allarity Therapeutics Announces Participation in Pharma Partnering Summit US
TARPON SPRINGS, Fla., May 12, 2025 — Allarity Therapeutics, Inc. ('Allarity' or the 'Company') (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—today announced the Company's CEO, Thomas Jensen, will deliver a company overview focused on stenoparib and the Company's DRP® companion diagnostic platform and conduct one-on-one meetings at the Pharma Partnering Summit US. The event is a business development and licensing conference for executives of biotechnology and pharmaceutical companies, taking place May 14–15 in San Diego, CA. Registrants can request one-on-one meetings with Thomas Jensen, and more information about the summit can be found at the following link: About Stenoparib Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. At present, tankyrases are attracting significant attention as emerging therapeutic targets for cancer, principally due to their role in regulating the WNT signaling pathway. Aberrant Wnt/β-catenin signaling has been implicated in the development and progression of numerous cancers. By inhibiting PARP and blocking WNT pathway activation, stenoparib's unique therapeutic action shows potential as a promising therapeutic for many cancer types, including ovarian cancer. Allarity has secured exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. and was formerly known under the names E7449 and 2X-121. About the Drug Response Predictor – DRP® Companion Diagnostic Allarity uses its drug-specific DRP® to select those patients who, by the gene expression signature of their cancer, may have a high likelihood of benefiting from a specific drug. By screening patients before treatment, and only treating those patients with a sufficiently high, drug-specific DRP score, the therapeutic benefit rate may be enhanced. The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes. DRP is based on messenger RNA expression profiles from patient biopsies. The DRP® platform has shown an ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients across dozens of clinical studies (both retrospective and prospective). The DRP platform, which may be useful in all cancer types and is patented for dozens of anti-cancer drugs, has been extensively published in the peer-reviewed literature. About Allarity Therapeutics Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. The Company is focused on development of stenoparib, a novel PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP® technology to develop a companion diagnostic that can be used to select those patients expected to derive the greatest clinical benefit from stenoparib. Allarity is headquartered in the U.S., with a research facility in Denmark, and is committed to addressing significant unmet medical needs in cancer treatment. For more information, visit Follow Allarity on Social Media LinkedIn: Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company's current expectations or forecasts of future events. The words 'anticipates,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intends,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predicts,' 'project,' 'should,' 'would' and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, corporate presentation highlighting Allarity's clinical strategy and development progress for stenoparib. Any forward-looking statements in this press release are based on management's current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, statements concerning clinical development progress, trial design and enrollment for stenoparib, the potential benefits of DRP®-guided therapy, and efforts to achieve regulatory milestones. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled 'Risk Factors' in our Form 10-K annual report filed with the Securities and Exchange Commission (the 'SEC') on March 31, 2025, available at the SEC's website at and as well as discussions of potential risks, uncertainties and other important factors in the Company's subsequent filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law. ### Company Contact: [email protected] Media Contact: Thomas Pedersen Carrotize PR & Communications +45 6062 9390 [email protected]
Yahoo
12-05-2025
- Business
- Yahoo
Allarity Therapeutics Announces Participation in Pharma Partnering Summit US
TARPON SPRINGS, Fla., May 12, 2025 -- Allarity Therapeutics, Inc. ('Allarity' or the 'Company') (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—today announced the Company's CEO, Thomas Jensen, will deliver a company overview focused on stenoparib and the Company's DRP® companion diagnostic platform and conduct one-on-one meetings at the Pharma Partnering Summit US. The event is a business development and licensing conference for executives of biotechnology and pharmaceutical companies, taking place May 14–15 in San Diego, CA. Registrants can request one-on-one meetings with Thomas Jensen, and more information about the summit can be found at the following link: About StenoparibStenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. At present, tankyrases are attracting significant attention as emerging therapeutic targets for cancer, principally due to their role in regulating the WNT signaling pathway. Aberrant Wnt/β-catenin signaling has been implicated in the development and progression of numerous cancers. By inhibiting PARP and blocking WNT pathway activation, stenoparib's unique therapeutic action shows potential as a promising therapeutic for many cancer types, including ovarian cancer. Allarity has secured exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. and was formerly known under the names E7449 and the Drug Response Predictor – DRP® Companion DiagnosticAllarity uses its drug-specific DRP® to select those patients who, by the gene expression signature of their cancer, may have a high likelihood of benefiting from a specific drug. By screening patients before treatment, and only treating those patients with a sufficiently high, drug-specific DRP score, the therapeutic benefit rate may be enhanced. The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes. DRP is based on messenger RNA expression profiles from patient biopsies. The DRP® platform has shown an ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients across dozens of clinical studies (both retrospective and prospective). The DRP platform, which may be useful in all cancer types and is patented for dozens of anti-cancer drugs, has been extensively published in the peer-reviewed literature. About Allarity TherapeuticsAllarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. The Company is focused on development of stenoparib, a novel PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP® technology to develop a companion diagnostic that can be used to select those patients expected to derive the greatest clinical benefit from stenoparib. Allarity is headquartered in the U.S., with a research facility in Denmark, and is committed to addressing significant unmet medical needs in cancer treatment. For more information, visit Follow Allarity on Social MediaLinkedIn: Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company's current expectations or forecasts of future events. The words 'anticipates,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intends,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predicts,' 'project,' 'should,' 'would' and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, corporate presentation highlighting Allarity's clinical strategy and development progress for stenoparib. Any forward-looking statements in this press release are based on management's current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, statements concerning clinical development progress, trial design and enrollment for stenoparib, the potential benefits of DRP®-guided therapy, and efforts to achieve regulatory milestones. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled 'Risk Factors' in our Form 10-K annual report filed with the Securities and Exchange Commission (the 'SEC') on March 31, 2025, available at the SEC's website at and as well as discussions of potential risks, uncertainties and other important factors in the Company's subsequent filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law. ### Company Contact: investorrelations@ Media Contact: Thomas Pedersen Carrotize PR & Communications +45 6062 9390 tsp@ Attachment Allarity Therapeutics Announces Participation in Pharma Partnering Summit USSign in to access your portfolio
Channel Post MEA
17-04-2025
- Business
- Channel Post MEA
Milestone Systems Acquires Brighter AI
Milestone Systems recently acquired state-of-the-art anonymization technology brighter AI, opening up a range of new opportunities for video technology with anonymization capabilities and privacy enhancement, which protects data and enables full data privacy. The addition of brighter AI significantly strengthens Milestone's offerings for video management software, video surveillance as a service and video analytics and fuels the company's ongoing growth journey in and beyond security. Additionally, brighter AI's anonymization technology serves as a cornerstone of the recently announced data library and AI model training tool Project Hafnia. The advances of artificial intelligence raise concerns around data privacy across the world. One of the biggest challenges in developing AI solutions is finding and accessing sufficient data that can be used. Without data, there are no AI models to train, which are essential for existing AI technologies such as ChatGPT and Copilot. This challenge is particularly significant in video data, where it is even more difficult to find data that does not contain sensitive personal information. The solution lies within regulatory-compliant data and this is exactly what brighter AI's anonymization technology privacy-by-design tool developed by brighter AI further solidifies Milestone's position as a leading Responsible Technology company. Combining two European tech leaders with a focus on taking a responsible approach to AI development will be a significant contribution to global AI and tech landscape. 'brighter AI is a perfect match for Milestone. Their proven technology is top-notch and will give us a wider offering to existing and future technology partners and customers. The anonymization tool for video technology will also enhance our focus on responsible technology. Even more important, our two company cultures are highly compatible. Having known brighter AI for a while, as we have an established collaboration on Project Hafnia, I have complete faith that this will be a great benefit for all. I am indeed very pleased to welcome our new colleagues to Milestone,' says Thomas Jensen, CEO of Milestone. 'The acquisition of brighter AI sheds light on Milestone's vision of being a responsible video technology company, we understand how important privacy of data becomes when it comes to AI. Anonymization solutions will become a core pillar of our Project Hafnia platform that is set to redefine how compliant, high-quality video data is used to train AI. Secure, ethical, and transformative visual AI is Milestone's commitment to upholding the highest standards of privacy with video technology' says Louise Bou Rached, Director – Middle East, Turkey and Africa, Milestone Systems Founded in 2017 by Marian and Patrick Kern, brighter AI serves companies across various sectors and is the leading anonymization solution for video data based on artificial intelligence. For the solution Deep Natural Anonymization, which automatically detects a personal identifier such as a face and generates a synthetic replacement, brighter AI was named 'Europe's Hottest AI Startup' by Nvidia. 0 0
Mid East Info
17-04-2025
- Business
- Mid East Info
Milestone Systems acquires brighter AI adding state-of-the-art anonymization technology - Middle East Business News and Information
Milestone Systems recently acquired state-of-the-art anonymization technology brighter AI, opening up a range of new opportunities for video technology with anonymization capabilities and privacy enhancement, which protects data and enables full data privacy. The addition of brighter AI significantly strengthens Milestone's offerings for video management software, video surveillance as a service and video analytics and fuels the company's ongoing growth journey in and beyond security. Additionally, brighter AI's anonymization technology serves as a cornerstone of the recently announced data library and AI model training tool Project Hafnia. The advances of artificial intelligence raise concerns around data privacy across the world. One of the biggest challenges in developing AI solutions is finding and accessing sufficient data that can be used. Without data, there are no AI models to train, which are essential for existing AI technologies such as ChatGPT and Copilot. This challenge is particularly significant in video data, where it is even more difficult to find data that does not contain sensitive personal information. The solution lies within regulatory-compliant data and this is exactly what brighter AI's anonymization technology privacy-by-design tool developed by brighter AI further solidifies Milestone's position as a leading Responsible Technology company. Combining two European tech leaders with a focus on taking a responsible approach to AI development will be a significant contribution to global AI and tech landscape. 'brighter AI is a perfect match for Milestone. Their proven technology is top-notch and will give us a wider offering to existing and future technology partners and customers. The anonymization tool for video technology will also enhance our focus on responsible technology. Even more important, our two company cultures are highly compatible. Having known brighter AI for a while, as we have an established collaboration on Project Hafnia, I have complete faith that this will be a great benefit for all. I am indeed very pleased to welcome our new colleagues to Milestone,' says Thomas Jensen, CEO of Milestone. 'The acquisition of brighter AI sheds light on Milestone's vision of being a responsible video technology company, we understand how important privacy of data becomes when it comes to AI. Anonymization solutions will become a core pillar of our Project Hafnia platform that is set to redefine how compliant, high-quality video data is used to train AI. Secure, ethical, and transformative visual AI is Milestone's commitment to upholding the highest standards of privacy with video technology' says Louise Bou Rached, Director – Middle East, Turkey and Africa, Milestone Systems Founded in 2017 by Marian and Patrick Kern, brighter AI serves companies across various sectors and is the leading anonymization solution for video data based on artificial intelligence. For the solution Deep Natural Anonymization, which automatically detects a personal identifier such as a face and generates a synthetic replacement, brighter AI was named 'Europe's Hottest AI Startup' by Nvidia.
TECHx
08-04-2025
- Business
- TECHx
Milestone Systems Acquires Brighter AI to Enhance Video Privacy
Milestone Systems Acquires Brighter AI to Enhance Video Privacy News Desk - Share Milestone Systems has acquired Brighter AI, an anonymization technology company, opening new opportunities for video technology with enhanced privacy features. This acquisition strengthens Milestone's offerings in video management software, video surveillance as a service, and video analytics. It also supports the company's growth in security and beyond. Brighter AI's technology plays a key role in Milestone's Project Hafnia, a new data library and AI model training tool. As AI developments raise concerns over data privacy, particularly with video data, Brighter AI's solution offers a regulatory-compliant way to anonymize sensitive information. This ensures full data privacy, addressing a key challenge in AI model development—finding non-sensitive data for training. Data privacy is a major challenge in AI, especially with video content that often includes personal identifiers. Brighter AI's anonymization tool automatically detects and replaces these identifiers, making video data safe and compliant for AI use. This approach is essential for developing technologies like ChatGPT and Copilot. Thomas Jensen, CEO of Milestone Systems, said, 'Brighter AI's proven technology will expand our offerings and enhance our commitment to responsible technology. We've collaborated on Project Hafnia, and I'm confident this acquisition will bring great benefits to both teams.' Louise Bou Rached, Director for the Middle East, Turkey, and Africa at Milestone, added, 'Brighter AI's anonymization solutions will be a core part of Project Hafnia. This aligns with our goal to provide secure, ethical, and transformative visual AI, upholding the highest privacy standards.' Founded in 2017 by Marian and Patrick Kern, Brighter AI is a provider of anonymization solutions for video data. Its Deep Natural Anonymization technology, which automatically replaces personal identifiers like faces, earned it the title 'Europe's Hottest AI Startup' by Nvidia. This acquisition highlights Milestone's commitment to responsible AI development and privacy-first video technology.
